Search a ticker

Categories
Biotech Stocks Featured Investing Stock Market Today Stocks to Watch

Top Biotech Stocks Reporting Their Earnings This Week; Are They On Your List?

Could these biotech stocks be poised for market-beating performance?

biotech stocks to buy

Are These Top Biotech Stocks On The Top Of Your Mind This Week?

This week will be a week where we see many top biotech stocks reporting their earnings. No doubt, hopes of a vaccine breakthrough have boosted biotech stocks. As pharmaceutical and biotechnology companies begin to report their second-quarter earnings, the industry could also be facing some headwinds. 

Pharmaceuticals and biotech stocks have been propelled into the spotlight as the coronavirus pandemic spells the importance of vaccines and treatments. For this reason, companies that are working on Covid-19 related programs have seen their share prices soaring. But the truth is, we have yet to see any approved vaccines or treatments. It’s gonna take some time to complete clinical trials. Until there’s a commercialized vaccine in distribution, vaccine manufacturers will not be booking any revenue from it. On the treatment front, Gilead’s (GILD Stock Report) remdesivir appears to be working well on serious cases. This makes GILD stock one of the top biotech stocks to watch in the past few months.

The benefit of investing in large-cap biotech stocks is that they have a strong pipeline of drugs. And if they have an additional drug for Covid-19, even better. Their broader economic moats are making them a defensive investment. Yet they have a lot of potential upsides shall the Covid-19 initiatives materialize. Let’s take a closer look at a list of top biotech stocks that are set to disclose their earnings this week.

Read More

Top Biotech Stocks To Buy Now [Or Sell]: Pfizer

First, up the list, Pfizer (PFE Stock Report) was all over the news last week after encouraging results from the vaccine candidate co-developed with BioNTech (BNTX Stock Report). Following the positive news, the company received a further boost when the U.S. government promised to fund the companies $1.95 billion to secure 600 million doses of the vaccine, with the condition it receives approval from the FDA.

As a result, the two fold positive news gave PFE stocks a boost. Shares of PFE have since rebounded more than 30% since the March lows. The company is also reported to be in the midst of spinning off its less profitable segment to Mylan (MYL Stock Report). Once the spin-off is complete, it is possible that the pharmaceutical giant will be a much more profitable company. With the company’s strong pipeline of 91 drugs, and quite a number of them having strong growth potential, is PFE stock a buy?

Top Biotech Stocks To Buy Now [Or Sell]: AstraZeneca

Another pharmaceutical giant grabbed headlines last week was AstraZeneca (AZN Stock Report). This came after the interim results from the phase 1/2 trial of the company’s vaccine were very positive. As such, the company’s vaccine candidate AZD1222 is one of the two such candidates entering the third stage of trials. The strange thing here is that such news would typically push the stock up, but the stock went south instead. So, what happened?

As you may have known already, the drug had “minor side-effects” despite its ability to induce antibody and T-cell immune response. The fact that side effects were largely concealed made some investors wonder if they were being overly optimistic about the vaccine’s outcome. To be fair, nearly all phase-2 vaccines are exhibiting similar side-effects, and that includes Moderna as well. But I guess it’s fair to assume that many would rather get these side-effects than getting Covid-19.

[Read More] Top 5 Things To Know In The Stock Market This Week

Top Biotech Stocks To Buy Now [Or Sell]: Amgen

Next on the list, Amgen (AMGN Stock Report) is a biotech stock with strong dividend yield, and most importantly the company has seen its overall revenue increasing steadily. The company is currently partnering Adaptive Biotechnologies (ADPT Stock Report) to potentially treat or prevent Covid-19. The company’s strong cash position is also what makes it more attractive compared to other biotech stocks in the market.

There isn’t any major news that would trigger a huge price movement recently. Sales were flat during the first quarter. There are a lot of promising late-stage drugs that are expecting to get approvals soon. Amgen also has several rising star-drugs in its lineup. With all that in mind, it appears that Amgen’s pipeline could make them one of the best dividend stocks to have.

Top Biotech Stocks To Buy Now [Or Sell]: GlaxoSmithKline

Shares of GlaxoSmithKline (GSK Stock Report) have underperformed the industry so far this year. The stock has declined 14.1% against the industry’s rise of 0.8%. Given the scale, many would argue that this is quite a well-run company. From the financial front, the company has reported an 18.7% quarterly revenue growth and an admirable 15.3% profit margin. With almost ten pipeline drugs awaiting registration, investors should expect revenue growth in the next few years to be higher.

Given a strong pipeline of 37 drugs and 15 potential vaccines, the revenue growth is likely to continue, making GSK one of the best biotech stocks to watch in the market.

By Amos C

Amos is the global markets correspondent for StockMarket.com. His boots on the ground insight into emerging markets has given him the unique ability to stay ahead of new market trends and deliver timely data when it matters most. Based in Asia, Amos has made a point to monitor the foreign markets closely, dissect stock market trends and then apply them to the North American markets; in addition to global markets.

Amos has a deep-rooted background in foreign exchange and commodities. His previous experience working within the cryptocurrency arena has given him the advantage to identify the fast-moving stock market and financial trends. Amos calls Hong Kong home and has been a financial content writer for the last 3 years.

He has managed teams of international media strategists and financial writers to cover all top stories in the stock market each day. His skills include his tireless drive to find the most valid information and actionable details that investors can use to formulate valid decisions on stocks to buy or stocks to avoid. Furthermore, Amos’ ability to cover trending stories across the globe brings StockMarket.com a fresh perspective on key data and how it not only affects the North American markets but also how it could translate to the world markets alike.

Most of the time you can find him diving into corporate filings, focusing on fundamentals that could influence major market moves. One of his passions is researching technology and biotechnology stocks. Some of the most cutting-edge innovations have stemmed from these industries. While many don’t become industry blockbusters, the processes and applications of these innovations has led to some of the biggest developments known to man in the modern age. As a global correspondent, Amos has been able to see both sides of the story as it relates to world news and offers a true, personal approach, cutting through the noise of the mass media. He was integral in reporting on the Hong Kong uprising and doing first-hand research on international sentiment from the novel coronavirus.

In his free time, Amos is an avid fan of music and art and enjoys attending concerts.